ASCO GU 2023 Bladder Cancer - Results from #20

Viewing 21-40 of 54 articles

ASCO GU 2023: It's Time to Talk About Value-Based Care and Time Toxicity With Our Patients

ASCO GU 2023: Randomised Phase II Trial of Adaptive Image Guided Radiotherapy in Muscle Invasive Bladder Cancer: Late Toxicity and Cancer Outcomes

ASCO GU 2023: Neoadjuvant Pembrolizumab for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy

ASCO GU 2023: Innovative and Pragmatic Methods to Study BCG Unresponsive Nonmuscle-Invasive Bladder Cancer

ASCO GU 2023: A Phase II Trial of Risk-Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

ASCO GU 2023: Randomized Phase III Clinical Trial of Neoadjuvant Intravesical Mitomycin C Treatment in Patients with Primary Treatment Naïve NMIBC

ASCO GU 2023: Eliminating Differences in Outcomes by Race and Gender in Urothelial Carcinoma

ASCO GU 2023: Time to Event Following Bacillus Calmette-Guerin Therapy Initiation in Medicare Beneficiaries with Intermediate- to High-Risk Non-Muscle Invasive Bladder Cancer, 2010-2019

ASCO GU 2023: Baseline Characteristics from a Retrospective, Observational, US-Based, Multicenter, Real-World Study of Avelumab First-Line Maintenance in Locally Advanced/Metastatic Urothelial Carcinoma (PATRIOT-II)

ASCO GU 2023: HCRN GU14-188: Phase Ib/II Study of Neoadjuvant Pembrolizumab and Chemotherapy for T2-4aN0M0 Urothelial Cancer

ASCO GU 2023: Primary Analysis of TROPHY-U-01 Cohort 2, a Phase 2 Study of Sacituzumab Govitecan in Platinum-Ineligible Patients with Metastatic Urothelial Cancer That Progressed after Prior Checkpoint Inhibitor Therapy

ASCO GU 2023: Phase 2 Study of the Efficacy and Safety of Erdafitinib in Patients with Bacillus Calmette-Guérin-Unresponsive, High-Risk Non–muscle-Invasive Bladder Cancer with FGFR3/2 Alterations in THOR-2

ASCO GU 2023: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-up from the JAVELIN Bladder 100 Trial in Subgroups Defined by 1L Chemotherapy Regimen and Analysis of OS from Start of 1L Chemotherapy

ASCO GU 2023: The Impact of Blue Light Cystoscopy Use Among Patients with Non-Muscle Invasive Bladder Cancer In An Equal Access Setting

ASCO GU 2023: A Phase II Trial of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette-Guérin (BCG) for Patients with BCG-Exposed, High-Grade, Non-Muscle–invasive Bladder Cancer

ASCO GU 2023: Comparative Real-World Survival Outcomes of Muscle-Invasive Bladder Cancer Treated with Bladder-Only vs. Whole-Pelvis Concurrent Chemoradiation

ASCO GU 2023: Primary Analysis of TROPHY-U-01 Cohort 3, a Phase 2 Study of Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer That Progressed after Platinum-Based Therapy

ASCO GU 2023: Updated Outcomes in TROPHY-U-01 Cohort 1, a Phase 2 Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Cancer That Progressed after Platinum-Based Chemotherapy and a Checkpoint Inhibitor

ASCO GU 2023: Study of Real-World Treatment Patterns and Adherence to Bacillus Calmette-Guerin (BCG) in the Context of Guideline Recommendations for Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

ASCO GU 2023: A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (Interim Analysis)

1
2
3